Helen O. McCarthy

Researcher Next ID · RN-040431

Researcher · Biochemistry, Genetics and Molecular Biology

Belfast, Ireland

Accepting doctoral researchersFunding unknown

Research interests

Biochemistry, Genetics and Molecular Biology

Medicine

Pharmacology, Toxicology and Pharmaceutics

Advancements in Transdermal Drug Delivery

RNA Interference and Gene Delivery

Chronic Lymphocytic Leukemia Research

Advanced Drug Delivery Systems

Lymphoma Diagnosis and Treatment

Electrospinning of natural polymers for the production of nanofibres for wound healing applications
Materials Science and Engineering C · 2020 · https://doi.org/10.1016/j.msec.2020.110994
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study
Blood · 2020 · https://doi.org/10.1182/blood.2020006844
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study
Leukemia · 2019 · https://doi.org/10.1038/s41375-019-0602-x
Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study
The Lancet Haematology · 2019 · https://doi.org/10.1016/s2352-3026(19)30210-8
Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial
The Lancet Oncology · 2018 · https://doi.org/10.1016/s1470-2045(18)30618-1
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
New England Journal of Medicine · 2015 · https://doi.org/10.1056/nejmoa1509388
Hydrogel‐Forming Microneedle Arrays for Enhanced Transdermal Drug Delivery
Advanced Functional Materials · 2012 · https://doi.org/10.1002/adfm.201200864

No projects listed.